Halozyme Therapeutics, Inc. (HALO)
Halozyme Therapeutics, Inc. (HALO) is a Healthcare stock tracked by StreetAlpha. HALO reports earnings on Mon, Nov 2, 2026. The average 12-month price target from 5 analysts is $103.60, with a high of $115.00 and a low of $93.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in HALO, 100% of them bullish and 0% bearish. In the past 30 days there were 26 dark pool prints totaling $120.9M, the largest $37.8M.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on HALO in the past 90 days. The average target is $103.60, with a high of $115.00 and a low of $93.00.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 2 | HC Wainwright & Co. | Reiterated | Buy | $115 |
| Aug 8 | Leerink Partners | Upgrade | Buy | $110 |
| Aug 7 | TD Cowen | Maintained | Buy | $105 |
| Aug 7 | Citizens | Maintained | Buy | $93 |
| Aug 7 | Wells Fargo | Maintained | Hold | $95 |
Whale Options Flow
90DDark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HALO is in one of them and how their past HALO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered HALO in an article yet. Here's the latest on the wider market.
For informational purposes only. Not financial advice. Options flow and dark pool data are delayed and may be incomplete.